What Porton Advanced Solutions does

Porton Advanced Solutions is a privately held cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) founded in 2018 as a wholly-owned subsidiary of Porton Pharma Solutions, Ltd. (Shenzhen Stock Exchange: 300363). It is operationally headquartered in Cranbury, New Jersey (United States), with two cGMP manufacturing sites in Suzhou, China (Ascendas Park Campus and Mulberry Field Island / BioBay Campus). The company serves global pharmaceutical and biotechnology developers of advanced therapy medicinal products (ATMPs), serving 250+ customers across multiple modalities including cell therapies, gene therapies, mRNA therapeutics, oncolytic bacteria, and exosomes.

The company's core offering is an end-to-end ATMP platform spanning plasmids, viral vectors (lentivirus, AAV, oncolytic viruses, adenovirus), cell engineering (CAR-T, TCR-T, CAR-NK, TIL, MSC, HSC, iPSC-derived products), mRNA/LNP, bacterial vectors, and exosomes. Notable proprietary technology components include the LV-SMART® serum-free HEK293T suspension lentiviral platform (>5E07 TU/mL infectious titer, FDA DMF-registered MCB/WCB), the AAVantage® AI-guided AAV capsid library platform (co-developed with BioMap using a 100B-parameter multimodal LLM), an in vivo CAR-T LV capability at 1×10⁹ TU/mL with batch scales up to 1×10¹² TU, and clinical-grade MaxCyte ExPERT GTx flow electroporation (the first at a cell engineering CDMO in China). The firm supports iPSC-derived therapies at >1,000 batches/year scale and runs 215,000 sq ft of GMP space with 10 viral vector lines and 12 cell therapy suites (2 commercial). Quality systems are compliant with FDA, EU, and NMPA GMP requirements; 25 IND clearances have been supported with a stated 100% zero-deficiency submission success rate.

The business model combines several revenue streams: (1) fee-for-service CDMO contracts (quote-based, project-scoped) covering process development, GMP manufacturing, fill/finish, and analytical release for clinical and commercial programs; (2) sale of off-the-shelf FDA DMF-registered LV-SMART helper plasmids (VSV-G DMF #29485, Rev #29473, GagPol DMF #29421); (3) catalog research products (AAV packaging across 20+ serotypes at $1,399–$15,699 per unit, plasmid preparation, lentivirus, mRNA) with publicly listed pricing aimed at academic and industrial research customers; (4) pipeline licensing of internal and client CAR-T candidates (PAS-001 through PAS-011) to international innovators; and (5) managed Investigator-Initiated Trial (IIT) services bundling GMP manufacturing with regulatory, ethics/HGRAC submissions, PI selection, patient recruitment, and clinical data collection — most recently anchored by an MOU with Dark Horse Consulting Group (April 2026) targeting overseas sponsors entering China. Go-to-market is sales-led B2B with field account coverage, conference-driven demand generation (ASGCT 2024 Baltimore, 2026 Boston booth #831), gated scientific content (whitepapers, brochures, peer-reviewed publications), and channel partnerships with consulting firms (DHCG) and raw-material suppliers (T&L Biotechnology).

Name

Porton Advanced Solutions

Legal name

Porton Advanced Solutions LLC

Website

https://portonadvanced.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Porton Advanced Solutions is a privately held cell and gene therapy CDMO providing end-to-end cGMP manufacturing, process development, and analytical services for plasmids, viral vectors, cell therapies, mRNA, bacterial vectors, and exosomes to global pharmaceutical and biotech sponsors.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy CDMO

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)

akta.pro secondary industries

Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Cell therapy CDMO
• Gene therapy CDMO
• Plasmid manufacturing
• Viral vector production
• MRNA LNP services

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. CDMO Manufacturing Services: Fee-for-service contract development and GMP manufacturing for plasmids, viral vectors, cell therapies, mRNA, bacterial vectors, and exosomes, from process development through IND-enabling CMC, GMP production, fill/finish, and release testing. Quote-based, project-scoped engagements with milestone billing.
2. Pipeline Licensing Service: Licensing-out of client/internal cell therapy pipelines (e.g., PAS-001 NKG2DL CAR-T for glioblastoma/colorectal/HCC, PAS-009/PAS-010 Mesothelin CAR-T, PAS-011 CD19 CAR-T for R/R B-ALL which is NMPA-approved) to international innovators. Generates licensing/royalty revenue.
3. Off-the-Shelf Helper Plasmid Products: Sale of ready-to-use, FDA DMF-registered LV-SMART™ helper plasmids (VSV-G DMF #29485, Rev DMF #29473, GagPol DMF #29421) in 1mg, 5mg, and 10mg vials for lentiviral vector manufacturing.
4. Research & Preclinical Catalog Products: Catalogue sales of AAV packaging (20+ serotypes, $1,399–$15,699 per unit), plasmid DNA preparation (miniprep through industrial grade), lentivirus, and mRNA products to academic and industrial research customers with publicly listed unit pricing.
5. Investigator-Initiated Trial (IIT) End-to-End Services: Managed IIT service bundles covering GMP manufacturing, IIT application, ethics/HGRAC submissions, PI and site selection, patient recruitment, clinical data collection, and analysis — coordinated with clinical/nonclinical CRO partners as project-managed services.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

Porton Advanced Solutions provides end-to-end contract development and manufacturing (CDMO) services for advanced therapy medicinal products (ATMPs), spanning plasmid DNA, lentiviral and AAV viral vectors, mRNA/LNP, bacterial vectors, exosomes, and engineered cell therapies (CAR-T, TCR-T, CAR-NK, TIL, MSC, iPSC-derived). The company operates from US headquarters in Cranbury, NJ and two cGMP manufacturing sites in Suzhou, China, offering process development, analytical/QC testing, GMP manufacturing, fill/finish, regulatory support (NMPA/FDA/EMA), and pipeline licensing for cell and gene therapy developers worldwide.

Product overview

Porton Advanced Solutions delivers an integrated platform-plus-modules ATMP CRO/CDMO architecture organized around three end-to-end service pillars: Research & Preclinical Services (vector construction, virus packaging, mRNA and LNP, gene editing, off-the-shelf products), CDMO Solutions (Cell Engineering CMC Services, Plasmid, Lentivirus, mRNA and LNP, Bacterial Vector, Exosome, iPSC-derived Cell Therapies, GMP Lentivirus Helper Plasmids, LV-SMART®-LVVs Suspension Production Platform, Adeno-Associated Virus), and Innovative Services (Integrated CMC Service for Investigator-Initiated Clinical Trials, Pipeline Licensing Service, Analytical Development and Testing). The LV-SMART®-LVVs Suspension Production Platform and AAVantage® Novel AAV Capsid Library Platform function as cross-cutting proprietary platforms that power the Lentivirus and AAV CDMO modules respectively. GMP Manufacturing (160,000 m² across two Suzhou sites) and the seven Functional Analytical Platforms (Physicochemical & Characterization, Microbiology, Molecular Studies, Biochemical, Cell Function, FACS) underpin all modules with shared QC, Process Development, and Quality Systems infrastructure. The offering is a single integrated CDMO platform with named product modules rather than a unified packaged product, supported by Pipeline Licensing of CAR-T candidates (PAS-001 to PAS-011) for in-licensing partners.

Differentiator

Problem solved

Functional benefit

Brands

• LV-SMART®: Proprietary HEK293T-based lentiviral vector suspension, serum-free GMP manufacturing platform developed by Porton Advanced, with FDA DMF-registered master cell bank.
• AAVantage®

Products and services

• Cell Engineering CMC Services End-to-end CMC services for engineered cell therapies including CAR-T, TCR-T, CAR-NK, MSC, TIL, NK, and iPSC-derived cell products, with full process development, cGMP manufacturing, testing, and regulatory assistance for global cell therapy developers.
• Plasmid CDMO Plasmid DNA manufacturing service for naked plasmid DNA, mRNA, AAV, lentiviral, and episomal iPSC reprogramming vectors, including microbial cell banking, GMP manufacturing (100mg-10g/batch), analytical development, and CMC writing.
• Lentiviral Vector CDMO End-to-end lentiviral vector CDMO service for CAR-T, TCR-T, CAR-NK, genetically modified MSC/HSC, and in vivo CAR-T applications, powered by the proprietary LV-SMART® suspension platform with adherent and suspension systems, ten viral vector GMP production suites, and analytics.
• mRNA and LNP CDMO End-to-end CRO and CDMO service for mRNA therapeutics including in vitro transcription, LNP encapsulation, plasmid linearization, capping/tailing, multi-step purification, LNP formulation, and fill/finish for both research-grade and GMP production.
• Bacterial Vector CDMO Integrated CMC service for live and live-attenuated bacterial vectors used in gene therapy, oncolytic bacterial therapy, and vaccines, covering strain construction, microbial banking, process development, GMP production, analytical development, fill & finish, and regulatory submission for Salmonella, E. coli, Listeria, and related strains.
• Exosome CDMO

Quantifiable outcome

• 100% submission success rate (zero-deficiency IND filings)
• +6 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature8 records

Partnerships

Eleven partnerships are on record, tiered core — exclusive cdmo partnership for yb1-x7 dual-filing program, flagship — strategic gtm alliance for global cell & gene therapy sponsors entering china, minor — affiliated consulting practices within the dhcg group that may co-engage on porton advanced client programs, flagship — integrated cgt supply chain partnership, core — strategic enterprise partnership for in vivo car-t, core — exclusive cdmo partnership for nk and car-nk pipeline, important — ophthalmic cell therapy co-development, core — first-in-china clinical-grade flow electroporation capability, core — ai-guided aav library co-development, minor — gene and cell engineering collaboration and minor — cgt raw materials alliance.

• Salvectors (Shaoxing Salvectors Biotechnology Ltd.)core — exclusive cdmo partnership for yb1-x7 dual-filing programStrategic or Co-development Partner · 20 May 2026Exclusive CDMO partner for Salvectors' YB1-X7 Injection, an oncolytic bacteria therapy (Salmonella-based YB1-v3.0 platform). Porton Advanced provided end-to-end CMC services including strain construction, process development, GMP production, quality studies, release testing, and regulatory submission support, achieving dual US FDA + China NMPA IND clearance in solid tumors.
• Dark Horse Consulting Group (DHCG)flagship — strategic gtm alliance for global cell & gene therapy sponsors entering chinaStrategic or Co-development Partner · 26 April 2026Signed a Memorandum of Understanding on April 26, 2026, to accelerate the development and clinical translation of cell and gene therapies globally, with particular emphasis on enabling Investigator-Initiated Trials (IITs) in China. Combines DHCG's regulatory, CMC, nonclinical, clinical, quality & compliance, supply chain, commercial launch, and business analytics consulting with Porton Advanced's end-to-end GMP manufacturing infrastructure (lentiviral vectors, AAV, mRNA/LNP, plasmids, engineered cell therapies including CAR-T, CAR-NK, and iPSC-derived products). Porton Advanced brings 24 IND clearances across NMPA and FDA and experience supporting over 30 IITs to date.
• DHCG business units (DHC, BioTechLogic, Converge Consulting, Bruder Consulting & Venture Group, CJP)minor — affiliated consulting practices within the dhcg group that may co-engage on porton advanced client programsImplementation/ SI/ Consulting Partner · 26 April 2026Dark Horse Consulting Group comprises three core business units (DHC, BioTechLogic, Converge Consulting), with Bruder Consulting & Venture Group (regenerative medicine) and CJP joining as Dark Horse Consulting companies in early 2026. These units extend DHCG's subject-matter expertise across strategy, operations, quality, regulatory, manufacturing, supply chain, commercial launch, and business optimization for biopharma clients engaged with Porton Advanced's CDMO services.
• T&L biotechnology (T&L Biotechnology Ltd.)flagship — integrated cgt supply chain partnershipStrategic or Co-development Partner · 12 March 2026Strategic partnership announced March 12, 2026 to create a fully integrated CGT supply chain solution from critical raw materials to commercial manufacturing. T&L brings upstream GMP-grade raw materials (cell separation & activation magnetic beads, recombinant proteins, serum-free medium, cell culture kits), while Porton Advanced contributes downstream process development and large-scale manufacturing. Joint process optimization and quality control help clients overcome technical hurdles and shorten timelines.
• CSPC Pharmaceutical Group Limitedcore — strategic enterprise partnership for in vivo car-tStrategic or Co-development Partner · 29 January 2026CDMO services for CSPC's SYS6055 Injection, the first in vivo CAR-T therapy approved for clinical trials in China, indicated for relapsed/refractory aggressive B-cell lymphoma. Porton Advanced provided plasmid, lentiviral vector, and full CMC support.
• Gene MiNK Biotechnology (Beijing Gene MiNK Biotechnology Co., Ltd.)core — exclusive cdmo partnership for nk and car-nk pipelineStrategic or Co-development Partner · 11 December 2025Exclusive CDMO partner for Gene MiNK's NK cell therapy pipeline: QM101 Cell Injection (feeder-free, serum-free autologous NK for solid tumors) and QM103 Cell Injection (BCMA-targeted CAR-NK for RRMM). Both secured NMPA IND clearance. End-to-end support from plasmids to lentiviral vectors to CAR-NK manufacturing delivered in 10 months.
• TongEye Medical Technology (TongEYE)important — ophthalmic cell therapy co-developmentStrategic or Co-development Partner · 15 May 2025Collaboration announced May 15, 2025 to accelerate development of iPSC-derived retinal pigment epithelium cell (RPEC) transplantation therapy for blinding eye diseases such as age-related macular degeneration (AMD). Porton Advanced provides end-to-end CDMO services including iPSC reprogramming and cell banking, process optimization for RPE-directed differentiation, GMP manufacturing, rigorous quality studies, and IND application support. TongEYE contributes a proprietary induction method that shortens RPE differentiation from 120–150 days to ~25 days.
• MaxCytecore — first-in-china clinical-grade flow electroporation capabilityTechnology or Integration · 25 June 2024Porton Advanced introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument into its cell engineering platform, becoming the first cell engineering CDMO in China with this clinical-grade flow electroporation system. Supports flexible transfection volumes from research through cGMP production. Porton Advanced collaborates with MaxCyte's technical and compliance teams on process development and clinical production for multiple cell engineering projects at IIT, IND, and clinical-trial stages.
• BioMapcore — ai-guided aav library co-developmentStrategic or Co-development Partner · 8 November 2023Strategic partnership announced November 8, 2023 to co-develop AI-driven AAV design solutions. BioMap contributes a 100B-parameter multimodal foundation model trained on 20M AAV viability data points and 3B protein data, covering 10+ serotypes with tissue-specific libraries. Porton Advanced contributes AAV capsid library plasmid construction, virus packaging, gene synthesis, and screening (in vivo NHP/mouse, in vitro 3D culture/organoid) to identify and validate candidate variants.
• DanausGTminor — gene and cell engineering collaborationStrategic or Co-development Partner · 2 March 2023Collaboration announced March 2, 2023 to accelerate the development of gene and cell engineering programs by combining DanausGT's pipeline with Porton Advanced's CDMO platform.
• Yinjia Biosciencesminor — cgt raw materials allianceStrategic or Co-development Partner · 25 February 2023Partnership announced February 25, 2023 to enhance Porton Advanced's CDMO technology platform through Yinjia Biosciences' CGT raw materials and process solutions.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Cobra Biologics (Charles River): Specialized viral vector and plasmid CDMO, now part of Charles River. Directly comparable to Porton Advanced's plasmid and LV/AAV CDMO modules for gene therapy developers.
• WuXi Advanced Therapies (WuXi AppTec ATU): The largest Chinese ATMP CDMO, providing plasmid, viral vector, and cell therapy manufacturing globally. Most directly comparable to Porton Advanced given the China-based GMP footprint and overlapping plasmid/LV/AAV/cell therapy offerings.
• GenScript ProBio: CDMO division of GenScript offering plasmid, viral vector, and cell therapy CMC services. Comparable in modality breadth (plasmid → LV → cell therapy) and in serving both Chinese and global CGT sponsors.
• AGC Biologics: Global CDMO with cell and gene therapy capabilities, including viral vector and cell therapy manufacturing. Comparable as a multi-modality CGT CDMO serving similar biotech and pharma customers across geographies.

Broad incumbents

• Catalent (Novo Holdings): Large global CDMO with viral vector, cell therapy, and plasmid CDMO services, recently acquired by Novo Holdings. Competes with Porton Advanced for large commercial-stage CGT manufacturing programs and brings deeper commercial-scale experience.
• Lonza: One of the largest global CDMOs with significant cell and gene therapy capacity via its Cell & Gene Technologies platform. Competes at the upper end of commercial-stage CGT manufacturing where Porton Advanced is still building share.
• Charles River Laboratories: Global CRO/CDMO with cell and gene therapy manufacturing, including viral vector CDMO. Overlaps with Porton Advanced's LV/AAV offering as part of a broader life-sciences services portfolio.

Emerging players

• Cellares: Emerging cell therapy CDMO focused on automated, high-throughput cell therapy manufacturing. Competes with Porton Advanced on cell engineering CMC services, particularly autologous CAR-T and CAR-NK programs.
• Resilience: Manufacturing technology company offering end-to-end biologics and cell/gene therapy services including viral vectors. Comparable to Porton Advanced's integrated CDMO approach and modality breadth.

Others

• MaxCyte: Provider of clinical-grade flow electroporation technology, used by Porton Advanced in its cell engineering platform. A technology partner rather than direct competitor, but it represents a key infrastructure dependency and signals the broader CGT CDMO ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/porton-advanced

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Porton Advanced Solutions